Abstract: The invention provides LRP5-binding polypeptides, and more specifically LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.

Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.

Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Abstract: VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

Abstract: The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least one, preferably at least two, attachment point(s) or conjugation site(s). In particular, the technology provides a molecule comprising at least one protein-based building block, wherein the at least one protein-based building block: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg/ml or more, measured in an aqueous solution at room temperature; and does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5×10?4 mol/litre.

Abstract: The present technology relates to polypeptides binding to the neonatal Fc receptor. More particularly, the present technology provides polypeptides binding to the neonatal Fc receptor and comprising (i) at least one domain comprising a serum albumin protein and/or at least one domain specifically binding to a serum albumin protein and (ii) an Fc domain of an immunoglobulin G (IgG).

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.

Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.

Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.

Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.

Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Abstract: Polypeptides are provided that bind CD123 on a target cell and the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of CD123 associated cancers or inflammatory conditions.

Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).

Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Abstract: The present invention is based on the finding that administration of polypeptides comprising two immunoglobulin single variable domains (ISVD) against von Willebrand Factor (vWF) to human patients with an initial episode of thrombotic thrombocytopenic purpura (TTP) episode results in improved outcomes, including a faster time to platelet count response lower proportion of patients with either death, recurrence or a major thromboembolic event (TE) during the treatment period, lower recurrence rate, and prevention of refractoriness. The invention provides a polypeptide comprising two ISVD against vWF for use in treating a vWF-related disease, preferably TTP, in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.

Abstract: The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine receptor CX3CR1 and an optimized ISVD binding to albumin. The present technology also relates to a composition of a polypeptide; a polynucleotide encoding a polypeptide; a host or host cell comprising a polynucleotide; a method for producing a polypeptide or composition; and a polypeptide, polynucleotide or composition for use in prevention, therapy and diagnosis of a disease or disorder.

Abstract: The present technology provides immunoglobulin single variable domains (ISVDs) binding both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell. It also relates to polypeptides comprising an ISVD according to the present technology and at least one ISVD capable of binding to an antigen on a target cell. The present technology further provides nucleic acids encoding said ISVDs or polypeptides as well as vectors, hosts and methods to produce these ISVDs or polypeptides. Moreover, the present technology relates to methods for treatment making use of the ISVDs or polypeptides of the present technology.

Abstract: The present technology provides T cell recruiting polypeptides that specifically bind to the constant domain of a human and of a non-human primate TCR. The present technology also provides nucleic acids, vectors, and compositions. The polypeptides can be used in methods for treatment of cancer.